Patents Assigned to TRT PHARMA INC.
  • Publication number: 20160083388
    Abstract: There is provided modulators of Nrf2 protein which comprises a compound which binds at least one of the BTB domain, IVR domain and Kelch domain of Keap1 protein, activating or inhibiting Nrf2. There is also provided pharmaceutical compositions containing the modulators, as well as uses and method of use of the modulators for the treatment of conditions.
    Type: Application
    Filed: August 13, 2015
    Publication date: March 24, 2016
    Applicant: TRT PHARMA INC.
    Inventors: Gerald BATIST, Jian Hui WU
  • Patent number: 9139592
    Abstract: The present invention is directed to a pharmaceutical composition comprising the following compound or a pharmaceutically acceptable salt thereof. The compound is a modulator of Nrf2 protein and binds at least one of the BTB domain, IVR domain and Kelch domain of Keap1 protein, activating or inhibiting Nrf2.
    Type: Grant
    Filed: May 31, 2011
    Date of Patent: September 22, 2015
    Assignee: TRT PHARMA INC.
    Inventors: Gerald Batist, Jian Hui Wu
  • Patent number: 8470889
    Abstract: The present invention relates to the synthesis of a series of ionone and curcumin derivatives as multi-targeting agents effective against both hormone-sensitive and hormone-independent cancers. In particular, the present invention is directed to a distinct class of bifunctional antiandrogens, which inhibit both AR and IKBkinases (IKK). A series of ionone-based chalcones were synthesized and their in vitro cytotoxicity against prostate cancer cell lines were demonstrated. A series of derivatives formed by reacting ionone-based chalcones and hydrazines demonstrate substantial antiproliferative activities in prostate cancer, breast cancer and lung cancer cell lines.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: June 25, 2013
    Assignee: TRT Pharma Inc.
    Inventors: Jian Hui Wu, GĂ©rald Batist, Jinming Zhou, Guoyan Geng, Rongtuan Lin, Yi Li
  • Publication number: 20130143933
    Abstract: The present document describes a cancer mutation-selective chemosensitizer that comprise compounds for restoring association between mutated keap1 protein and Nrf2 protein, and inhibition of Nrf2 functions. The present document also describes composition of matter containing the compounds, as well as methods of medical treatment for treating diseases such as cancer with the compounds.
    Type: Application
    Filed: November 9, 2012
    Publication date: June 6, 2013
    Applicant: TRT Pharma Inc.
    Inventor: TRT Pharma Inc.
  • Publication number: 20110230488
    Abstract: The present invention relates to the synthesis of a series of ionone and curcumin derivatives as multi-targeting agents effective against both hormone-sensitive and hormone-independent cancers. In particular, the present invention is directed to a distinct class of bifunctional antiandrogens, which inhibit both AR and IKBkinases (IKK). A series of ionone-based chalcones were synthesised and their in vitro cytotoxicity against prostate cancer cell lines were demonstrated. A series of derivatives formed by reacting ionone-based chalcones and hydrazines demonstrate substantial antiproliferative activities in prostate cancer, breast cancer and lung cancer cell lines.
    Type: Application
    Filed: November 25, 2009
    Publication date: September 22, 2011
    Applicant: TRT PHARMA INC.
    Inventors: Jian Hui Wu, Gerald Batist, Jinming Zhou, Guoyan Geng, Rongtuan Lin